Literature DB >> 15159060

The alternative pathway of complement in disease: opportunities for therapeutic targeting.

V Michael Holers1, Joshua M Thurman.   

Abstract

The alternative pathway of complement is receiving increasing attention as a therapeutic target because of recent findings in several animal models that support its essential role in tissue injury and disease pathogenesis. Although the contribution of alternative pathway activation to serum complement activation in vitro is relatively modest, its role in generating activated pro-inflammatory fragments at extra-vascular sites is substantial. Several potential mechanisms might underlie this exaggerated effect, including local synthesis of alternative pathway components, disease-induced alterations of regulatory proteins, and influx of inflammatory cells that contain alternative pathway components into sites of injury. This review examines several animal models in which the alternative pathway is centrally involved in disease pathogenesis and which suggest a potential role for alternative pathway inhibitors as therapies for human disease. It is also expected that several clinically relevant studies will be presented at the XXth International Complement Workshop that will identify additional areas of interest with regard to this pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15159060     DOI: 10.1016/j.molimm.2004.03.012

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  32 in total

1.  Targeted modulation of the neuroinflammatory response after spinal cord injury: the ongoing quest for the "holy grail".

Authors:  Philip F Stahel; Michael A Flierl
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

Review 2.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

Review 3.  Complement receptors and the shaping of the natural antibody repertoire.

Authors:  V Michael Holers
Journal:  Springer Semin Immunopathol       Date:  2004-12-22

Review 4.  [The relevance of the inflammatory response in the injured brain].

Authors:  O I Schmidt; I Leinhase; E Hasenboehler; S J Morgan; P F Stahel
Journal:  Orthopade       Date:  2007-03       Impact factor: 1.087

5.  Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?

Authors:  Kate Smith-Jackson; Kevin J Marchbank
Journal:  Ann Transl Med       Date:  2018-11

6.  The Relationship of Longitudinal Levels of Complement Bb During Pregnancy with Preeclampsia.

Authors:  Anne M Lynch; Brandie D Wagner; Patricia C Giclas; Nancy A West; Ronald S Gibbs; V Michael Holers
Journal:  Am J Reprod Immunol       Date:  2015-10-29       Impact factor: 3.886

7.  Macrophage-produced IL-12p70 mediates hemorrhage-induced damage in a complement-dependent manner.

Authors:  Diana J Hylton; Sara M Hoffman; N Van Rooijen; Stephen Tomlinson; Sherry D Fleming
Journal:  Shock       Date:  2011-02       Impact factor: 3.454

8.  Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.

Authors:  Xianzhen Hu; Stephen Tomlinson; Scott R Barnum
Journal:  Neurosci Lett       Date:  2012-10-16       Impact factor: 3.046

9.  Variability and action mechanism of a family of anticomplement proteins in Ixodes ricinus.

Authors:  Bernard Couvreur; Jérôme Beaufays; Cédric Charon; Kathia Lahaye; François Gensale; Valérie Denis; Benoît Charloteaux; Yves Decrem; Pierre-Paul Prévôt; Michel Brossard; Luc Vanhamme; Edmond Godfroid
Journal:  PLoS One       Date:  2008-01-02       Impact factor: 3.240

10.  Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.

Authors:  Xianzhen Hu; V Michael Holers; Joshua M Thurman; Trent R Schoeb; Theresa N Ramos; Scott R Barnum
Journal:  Mol Immunol       Date:  2013-01-20       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.